Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018 / 임상당뇨병
Journal of Korean Diabetes
; : 6-9, 2019.
Article
en Ko
| WPRIM
| ID: wpr-761472
Biblioteca responsable:
WPRO
ABSTRACT
In 2018, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a consensus recommendation on management of hyperglycemia. This consensus report emphasized the need for patient-centered management considering multimorbidity and individual patient preferences and barriers. Patients with type 2 diabetes with established atherosclerotic cardiovascular disease who fail to control blood glucose with the initial glucose-lowering medication are recommended a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist. For patients with chronic kidney disease and heart failure, SGLT2 inhibitors are recommended. In patients who need an injectable medication, GLP-1 receptor agonists are the preferred choice over insulin. In this section, we summarize “Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).”
Palabras clave
Texto completo:
1
Banco de datos:
WPRIM
Asunto principal:
Glucemia
/
Enfermedades Cardiovasculares
/
Comorbilidad
/
Atención Dirigida al Paciente
/
Consenso
/
Diabetes Mellitus
/
Insuficiencia Renal Crónica
/
Aterosclerosis
/
Péptido 1 Similar al Glucagón
/
Prioridad del Paciente
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
Ko
Revista:
Journal of Korean Diabetes
Año:
2019
Tipo del documento:
Article